Key result
A multicenter matched-pair study allocated 137 patients with hypertrophic cardiomyopathy to 2 years of treatment with either verapamil or propranolol, with 37 pairs completing the follow-up.
Why the study?
Does verapamil improve symptoms and clinical parameters compared to propranolol in patients with hypertrophic cardiomyopathy?
Population
137 patients with hypertrophic cardiomyopathy (37 matched pairs completed the 2-year follow-up)
Comparison
Verapamil (mean 493 +/- 136 mg/day) for 2 years vs Propranolol (mean 340 +/- 135 mg/day) for 2 years
Design
Cohort
Follow-up
2 years
Authors
Loading...
Supports verapamil preference for HCM symptoms; hypothesis-generating and should not yet change practice.
Observational (n=137)
Yes
Does verapamil improve symptoms and clinical parameters compared to propranolol in patients with hypertrophic cardiomyopathy?
Long-term treatment with verapamil provides superior symptomatic improvement compared to high-dose propranolol in patients with hypertrophic cardiomyopathy.
Kober et al. (1988) conducted an observational in Hypertrophic cardiomyopathy (n=137). Verapamil vs. Propranolol (120 to 480 mg daily) was evaluated. A multicenter matched-pair study allocated 137 patients with hypertrophic cardiomyopathy to 2 years of treatment with either verapamil or propranolol, with 37 pairs completing the follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: